A comparative evaluation of a new automated assay for von Willebrand factor activity
Summary The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We ha...
Saved in:
| Published in | Haemophilia : the official journal of the World Federation of Hemophilia Vol. 19; no. 2; pp. 338 - 342 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.03.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1351-8216 1365-2516 1365-2516 |
| DOI | 10.1111/hae.12064 |
Cover
| Abstract | Summary
The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We have undertaken an evaluation of a new immunoturbidimetric VWF activity (VWF:Ac) assay (INNOVANCE® VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) relative to an established platelet‐based VWF:RCo method. Samples from 50 healthy normal subjects, 80 patients with VWD and 50 samples that exhibited ‘HIL’ (i.e. Haemolysis, Icterus or Lipaemia) were studied. VWF:Ac, VWF:RCo and VWF:Ag were performed on a CS–analyser (Sysmex UK Ltd, Milton Keynes, UK), all reagents were from Siemens Healthcare Diagnostics. The VWF:Ac assay, gave low intra‐ and inter‐assay imprecision (over a 31‐day period, n = 200 replicate readings) using commercial normal (Mean 96.2 IU dL−1, CV < 3.0%) and pathological (Mean 36.1 IU dL−1, CV < 3.5%) control plasmas. The normal and clinical samples exhibited good correlation between VWF:RCo (range 3–753 IU dL−1) and VWF:Ac (rs = 0.97, P < 0.0001), with a mean bias of 5.6 IU dL−1. Ratios of VWF:Ac and VWF:RCo to VWF:Ag in the VWD samples were comparable, although VWF:Ac had a superior lower level of detection to that of VWF:RCo (3% and 5% respectively). A subset (n = 97) of VWD and HIL samples were analysed for VWF:Ac at two different dilutions to assess the effect on relative potency, no significant difference was observed (P = 0.111). The INNOVANCE® VWF Ac assay was shown to be reliable and precise. |
|---|---|
| AbstractList | The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We have undertaken an evaluation of a new immunoturbidimetric VWF activity (VWF:Ac) assay (INNOVANCE(®) VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) relative to an established platelet-based VWF:RCo method. Samples from 50 healthy normal subjects, 80 patients with VWD and 50 samples that exhibited 'HIL' (i.e. Haemolysis, Icterus or Lipaemia) were studied. VWF:Ac, VWF:RCo and VWF:Ag were performed on a CS-analyser (Sysmex UK Ltd, Milton Keynes, UK), all reagents were from Siemens Healthcare Diagnostics. The VWF:Ac assay, gave low intra- and inter-assay imprecision (over a 31-day period, n = 200 replicate readings) using commercial normal (Mean 96.2 IU dL(-1), CV < 3.0%) and pathological (Mean 36.1 IU dL(-1), CV < 3.5%) control plasmas. The normal and clinical samples exhibited good correlation between VWF:RCo (range 3-753 IU dL(-1)) and VWF:Ac (rs = 0.97, P < 0.0001), with a mean bias of 5.6 IU dL(-1). Ratios of VWF:Ac and VWF:RCo to VWF:Ag in the VWD samples were comparable, although VWF:Ac had a superior lower level of detection to that of VWF:RCo (3% and 5% respectively). A subset (n = 97) of VWD and HIL samples were analysed for VWF:Ac at two different dilutions to assess the effect on relative potency, no significant difference was observed (P = 0.111). The INNOVANCE(®) VWF Ac assay was shown to be reliable and precise.The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We have undertaken an evaluation of a new immunoturbidimetric VWF activity (VWF:Ac) assay (INNOVANCE(®) VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) relative to an established platelet-based VWF:RCo method. Samples from 50 healthy normal subjects, 80 patients with VWD and 50 samples that exhibited 'HIL' (i.e. Haemolysis, Icterus or Lipaemia) were studied. VWF:Ac, VWF:RCo and VWF:Ag were performed on a CS-analyser (Sysmex UK Ltd, Milton Keynes, UK), all reagents were from Siemens Healthcare Diagnostics. The VWF:Ac assay, gave low intra- and inter-assay imprecision (over a 31-day period, n = 200 replicate readings) using commercial normal (Mean 96.2 IU dL(-1), CV < 3.0%) and pathological (Mean 36.1 IU dL(-1), CV < 3.5%) control plasmas. The normal and clinical samples exhibited good correlation between VWF:RCo (range 3-753 IU dL(-1)) and VWF:Ac (rs = 0.97, P < 0.0001), with a mean bias of 5.6 IU dL(-1). Ratios of VWF:Ac and VWF:RCo to VWF:Ag in the VWD samples were comparable, although VWF:Ac had a superior lower level of detection to that of VWF:RCo (3% and 5% respectively). A subset (n = 97) of VWD and HIL samples were analysed for VWF:Ac at two different dilutions to assess the effect on relative potency, no significant difference was observed (P = 0.111). The INNOVANCE(®) VWF Ac assay was shown to be reliable and precise. The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We have undertaken an evaluation of a new immunoturbidimetric VWF activity (VWF:Ac) assay (INNOVANCE(®) VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) relative to an established platelet-based VWF:RCo method. Samples from 50 healthy normal subjects, 80 patients with VWD and 50 samples that exhibited 'HIL' (i.e. Haemolysis, Icterus or Lipaemia) were studied. VWF:Ac, VWF:RCo and VWF:Ag were performed on a CS-analyser (Sysmex UK Ltd, Milton Keynes, UK), all reagents were from Siemens Healthcare Diagnostics. The VWF:Ac assay, gave low intra- and inter-assay imprecision (over a 31-day period, n = 200 replicate readings) using commercial normal (Mean 96.2 IU dL(-1), CV < 3.0%) and pathological (Mean 36.1 IU dL(-1), CV < 3.5%) control plasmas. The normal and clinical samples exhibited good correlation between VWF:RCo (range 3-753 IU dL(-1)) and VWF:Ac (rs = 0.97, P < 0.0001), with a mean bias of 5.6 IU dL(-1). Ratios of VWF:Ac and VWF:RCo to VWF:Ag in the VWD samples were comparable, although VWF:Ac had a superior lower level of detection to that of VWF:RCo (3% and 5% respectively). A subset (n = 97) of VWD and HIL samples were analysed for VWF:Ac at two different dilutions to assess the effect on relative potency, no significant difference was observed (P = 0.111). The INNOVANCE(®) VWF Ac assay was shown to be reliable and precise. The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We have undertaken an evaluation of a new immunoturbidimetric VWF activity (VWF:Ac) assay (INNOVANCE ® VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) relative to an established platelet‐based VWF:RCo method. Samples from 50 healthy normal subjects, 80 patients with VWD and 50 samples that exhibited ‘HIL’ (i.e. Haemolysis, Icterus or Lipaemia) were studied. VWF:Ac, VWF:RCo and VWF:Ag were performed on a CS–analyser (Sysmex UK Ltd, Milton Keynes, UK), all reagents were from Siemens Healthcare Diagnostics. The VWF:Ac assay, gave low intra‐ and inter‐assay imprecision (over a 31‐day period, n = 200 replicate readings) using commercial normal (Mean 96.2 IU dL −1 , CV < 3.0%) and pathological (Mean 36.1 IU dL −1 , CV < 3.5%) control plasmas. The normal and clinical samples exhibited good correlation between VWF:RCo (range 3–753 IU dL −1 ) and VWF:Ac (rs = 0.97, P < 0.0001), with a mean bias of 5.6 IU dL −1 . Ratios of VWF:Ac and VWF:RCo to VWF:Ag in the VWD samples were comparable, although VWF:Ac had a superior lower level of detection to that of VWF:RCo (3% and 5% respectively). A subset ( n = 97) of VWD and HIL samples were analysed for VWF:Ac at two different dilutions to assess the effect on relative potency, no significant difference was observed ( P = 0.111). The INNOVANCE ® VWF Ac assay was shown to be reliable and precise. Summary The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease (VWD). However, the assay suffers from poor reproducibility and sensitivity at low levels of VWF and is labour intensive. We have undertaken an evaluation of a new immunoturbidimetric VWF activity (VWF:Ac) assay (INNOVANCE® VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) relative to an established platelet‐based VWF:RCo method. Samples from 50 healthy normal subjects, 80 patients with VWD and 50 samples that exhibited ‘HIL’ (i.e. Haemolysis, Icterus or Lipaemia) were studied. VWF:Ac, VWF:RCo and VWF:Ag were performed on a CS–analyser (Sysmex UK Ltd, Milton Keynes, UK), all reagents were from Siemens Healthcare Diagnostics. The VWF:Ac assay, gave low intra‐ and inter‐assay imprecision (over a 31‐day period, n = 200 replicate readings) using commercial normal (Mean 96.2 IU dL−1, CV < 3.0%) and pathological (Mean 36.1 IU dL−1, CV < 3.5%) control plasmas. The normal and clinical samples exhibited good correlation between VWF:RCo (range 3–753 IU dL−1) and VWF:Ac (rs = 0.97, P < 0.0001), with a mean bias of 5.6 IU dL−1. Ratios of VWF:Ac and VWF:RCo to VWF:Ag in the VWD samples were comparable, although VWF:Ac had a superior lower level of detection to that of VWF:RCo (3% and 5% respectively). A subset (n = 97) of VWD and HIL samples were analysed for VWF:Ac at two different dilutions to assess the effect on relative potency, no significant difference was observed (P = 0.111). The INNOVANCE® VWF Ac assay was shown to be reliable and precise. |
| Author | Peyvandi, F. Mackie, I. J. Machin, S. J. Lawrie, A. S. Stufano, F. Canciani, M. T. |
| Author_xml | – sequence: 1 givenname: A. S. surname: Lawrie fullname: Lawrie, A. S. email: andrew.lawrie@ucl.ac.uk organization: Haemostasis Research Unit, Department of Haematology, University College London, UK, London – sequence: 2 givenname: F. surname: Stufano fullname: Stufano, F. organization: U.O.S. Dipartimentale per l Diagnosi e la Terapia delle Coagulopatie, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione I.R.C.C.S. Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy – sequence: 3 givenname: M. T. surname: Canciani fullname: Canciani, M. T. organization: U.O.S. Dipartimentale per l Diagnosi e la Terapia delle Coagulopatie, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione I.R.C.C.S. Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy – sequence: 4 givenname: I. J. surname: Mackie fullname: Mackie, I. J. organization: Haemostasis Research Unit, Department of Haematology, University College London, UK, London – sequence: 5 givenname: S. J. surname: Machin fullname: Machin, S. J. organization: Haemostasis Research Unit, Department of Haematology, University College London, UK, London – sequence: 6 givenname: F. surname: Peyvandi fullname: Peyvandi, F. organization: Haemostasis Research Unit, Department of Haematology, University College London, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23205618$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMtP3DAQhy1ExfvAP1D5WA4BP2InOW5XPKqiIvE8WhPHVt0m8WI7C_vf17DAoVI7h5nR6PvN4dtFm6MfDUKHlBzTXCc_wRxTRmS5gXYol6JggsrNl13QomZUbqPdGH8RQnmmttA2y1NIWu-g2xnWflhAgOSWBpsl9FNe_Yi9xYBH84RhSn6AZDoMMcIKWx_wMgMPru9NG2DssAWd8jV3t3RptY8-WeijOXibe-ju7PR2flFcXp1_m88uC12ypiyE7oioRde2lSYNa0VZ86bjhIm6YkSXpGwIWCulpRYqJnUtKkG4hbbtWl0Tvoe-rP8ugn-cTExqcFGbvofR-CkqyuqmrJqmoRn9_IZO7WA6tQhugLBS7yYycLQGdPAxBmM_EErUi2WVLatXy5k9-YvVLr1aSwFc_7_Ek-vN6t-v1cXs9D1RrBMuJvP8kYDwW8mKV0I9_DhXZ9_n99f85quq-B8c7pu5 |
| CitedBy_id | crossref_primary_10_1002_rth2_12626 crossref_primary_10_1002_ajh_25393 crossref_primary_10_4103_njbcs_njbcs_60_21 crossref_primary_10_1016_j_pathol_2021_07_001 crossref_primary_10_1111_hae_13929 crossref_primary_10_1002_rth2_12141 crossref_primary_10_1111_jth_14345 crossref_primary_10_1111_jth_14429 crossref_primary_10_1517_21678707_2015_1066245 crossref_primary_10_1055_s_0044_1787841 crossref_primary_10_1111_jth_12964 crossref_primary_10_1111_hae_12443 crossref_primary_10_1016_j_thromres_2019_07_010 crossref_primary_10_1160_TH14_02_0108 crossref_primary_10_1016_j_pathol_2016_03_001 crossref_primary_10_1111_ijlh_12218 crossref_primary_10_1002_jha2_178 crossref_primary_10_1111_hae_13401 crossref_primary_10_1111_jth_14715 crossref_primary_10_1182_asheducation_2013_1_254 crossref_primary_10_1182_asheducation_2014_1_524 crossref_primary_10_1055_a_1806_9972 crossref_primary_10_1111_hae_14892 crossref_primary_10_1016_j_thromres_2014_09_024 crossref_primary_10_1016_S1773_035X_14_72524_9 crossref_primary_10_1007_s12185_014_1720_x crossref_primary_10_1111_ijlh_12540 crossref_primary_10_1111_hae_12380 crossref_primary_10_1111_ijlh_12220 crossref_primary_10_1111_hae_12937 crossref_primary_10_1111_bjh_13064 crossref_primary_10_1111_hae_12862 crossref_primary_10_1111_bjh_18080 crossref_primary_10_1111_hae_12900 crossref_primary_10_1016_j_thromres_2016_02_029 crossref_primary_10_1111_jth_14206 crossref_primary_10_1111_aor_12116 crossref_primary_10_1111_hae_12384 crossref_primary_10_1111_hae_12264 crossref_primary_10_2491_jjsth_31_409 crossref_primary_10_1016_j_thromres_2015_01_027 crossref_primary_10_1182_blood_2015_11_664680 crossref_primary_10_1111_ijlh_13445 crossref_primary_10_1016_j_thromres_2014_04_033 crossref_primary_10_1111_bjh_16681 crossref_primary_10_1182_blood_2013_06_498303 crossref_primary_10_21518_2307_1109_2022_12_2_79_102 crossref_primary_10_1016_j_transci_2018_07_005 crossref_primary_10_1093_jalm_jfae063 crossref_primary_10_1371_journal_pone_0171029 crossref_primary_10_1111_jth_15740 crossref_primary_10_1016_j_thromres_2014_05_020 crossref_primary_10_1111_jth_14971 crossref_primary_10_1007_s11239_019_01917_7 crossref_primary_10_1111_hae_12410 |
| Cites_doi | 10.1016/S0049-3848(09)70150-1 10.1056/NEJMra040403 10.1002/ajh.21405 10.1054/blre.1999.0116 10.1111/j.1365-2516.2010.02419.x 10.1055/s-0038-1651343 10.2307/2987937 10.1111/j.1538-7836.2010.04123.x 10.1055/s-0038-1645215 10.1055/s-0037-1614063 10.3109/00313029309084791 10.1111/j.1365-2516.2004.00894.x 10.1182/blood.V81.7.1787.1787 10.1097/00001721-200408000-00011 10.1172/JCI107465 10.1046/j.1365-2516.2002.00672.x 10.1055/s-0038-1642471 10.1111/j.1538-7836.2006.02146.x 10.1182/blood-2010-08-299016 10.1159/000214846 |
| ContentType | Journal Article |
| Copyright | 2012 Blackwell Publishing Ltd 2012 Blackwell Publishing Ltd. |
| Copyright_xml | – notice: 2012 Blackwell Publishing Ltd – notice: 2012 Blackwell Publishing Ltd. |
| DBID | BSCLL 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/hae.12064 |
| DatabaseName | Istex Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2516 |
| EndPage | 342 |
| ExternalDocumentID | 23205618 10_1111_hae_12064 HAE12064 ark_67375_WNG_FKCVR3SB_7 |
| Genre | article Research Support, Non-U.S. Gov't Evaluation Study Journal Article |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 29I 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EBX EGARE EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT 24P AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c4294-5cd0585dbb7c092b54839d30258720c40490aff66f1fa726c857503fabbdbc803 |
| IEDL.DBID | DR2 |
| ISSN | 1351-8216 1365-2516 |
| IngestDate | Fri Jul 11 03:17:52 EDT 2025 Mon Jul 21 05:43:36 EDT 2025 Thu Apr 24 22:50:37 EDT 2025 Tue Jul 01 03:34:07 EDT 2025 Wed Jan 22 16:23:43 EST 2025 Wed Oct 30 09:52:42 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2012 Blackwell Publishing Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4294-5cd0585dbb7c092b54839d30258720c40490aff66f1fa726c857503fabbdbc803 |
| Notes | istex:788083D56219CDEEE9E278B3B966F4C0AE902A6A ArticleID:HAE12064 ark:/67375/WNG-FKCVR3SB-7 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhae.12064 |
| PMID | 23205618 |
| PQID | 1289479991 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_1289479991 pubmed_primary_23205618 crossref_primary_10_1111_hae_12064 crossref_citationtrail_10_1111_hae_12064 wiley_primary_10_1111_hae_12064_HAE12064 istex_primary_ark_67375_WNG_FKCVR3SB_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2013 |
| PublicationDateYYYYMMDD | 2013-03-01 |
| PublicationDate_xml | – month: 03 year: 2013 text: March 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Haemophilia : the official journal of the World Federation of Hemophilia |
| PublicationTitleAlternate | Haemophilia |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993; 81: 1787-91. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-4. Federici AB. Classification of inherited von Willebrand disease and implications in clinical practice. Thromb Res 2009; 124(Suppl. 1): S2-6. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. Letter: a method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8. Baronciani L, Cozzi G, Canciani MT et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40. Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 2009; 121: 71-84. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14. Nichols WL, Rick ME, Ortel TL et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-70. Favaloro EJ, Grispo L, Dinale A, Berndt M, Koutts J. von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor. Pathology 1993; 25: 152-8. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-5. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev 1999; 13: 185-204. Flood VH, Gill JC, Morateck PA et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74. Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15: 505-11. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-5. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-16. Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217. Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-83. Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011; 17: 252-6. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician 1983; 32: 307-17. 2004; 10 1990; 63 1993; 25 2004; 351 2009; 84 1973; 52 2011; 117 1993; 81 2004; 15 2002; 8 1999; 13 2009; 121 1975; 34 2000; 84 1983; 32 2009; 124 2008; 21 2006; 4 2011; 17 1994; 71 2010; 8 e_1_2_6_21_1 e_1_2_6_20_1 Favaloro EJ (e_1_2_6_9_1) 2008; 21 e_1_2_6_8_1 Russell SD (e_1_2_6_10_1) 1993; 81 e_1_2_6_19_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_3_1 e_1_2_6_11_1 e_1_2_6_2_1 e_1_2_6_12_1 e_1_2_6_22_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1 |
| References_xml | – reference: Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21. – reference: Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. Letter: a method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8. – reference: Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94. – reference: Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14. – reference: Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993; 81: 1787-91. – reference: Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-4. – reference: Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217. – reference: Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-16. – reference: Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011; 17: 252-6. – reference: Flood VH, Gill JC, Morateck PA et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74. – reference: Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician 1983; 32: 307-17. – reference: Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 2009; 121: 71-84. – reference: Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev 1999; 13: 185-204. – reference: Nichols WL, Rick ME, Ortel TL et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-70. – reference: Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-83. – reference: Baronciani L, Cozzi G, Canciani MT et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40. – reference: Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15: 505-11. – reference: Federici AB. Classification of inherited von Willebrand disease and implications in clinical practice. Thromb Res 2009; 124(Suppl. 1): S2-6. – reference: Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-5. – reference: Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-5. – reference: Favaloro EJ, Grispo L, Dinale A, Berndt M, Koutts J. von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor. Pathology 1993; 25: 152-8. – volume: 8 start-page: 607 year: 2002 end-page: 21 article-title: Guidelines for the diagnosis and management of von Willebrand disease in Italy publication-title: Haemophilia – volume: 17 start-page: 252 year: 2011 end-page: 6 article-title: Evaluation of an automated platelet‐based assay of ristocetin cofactor activity publication-title: Haemophilia – volume: 84 start-page: 536 year: 2000 end-page: 40 article-title: Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease publication-title: Thromb Haemost – volume: 25 start-page: 152 year: 1993 end-page: 8 article-title: von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor publication-title: Pathology – volume: 13 start-page: 185 year: 1999 end-page: 204 article-title: Laboratory assessment as a critical component of the appropriate diagnosis and sub‐classification of von Willebrand's disease publication-title: Blood Rev – volume: 34 start-page: 306 year: 1975 end-page: 8 article-title: Letter: a method for assaying von Willebrand factor (ristocetin cofactor) publication-title: Thromb Diath Haemorrh – volume: 21 start-page: 178 year: 2008 end-page: 83 article-title: Lower limit of assay sensitivity: an under‐recognised and significant problem in von Willebrand disease identification and classification publication-title: Clin Lab Sci – volume: 71 start-page: 520 year: 1994 end-page: 5 article-title: A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis publication-title: Thromb Haemost – volume: 117 start-page: e67 year: 2011 end-page: 74 article-title: Gain‐of‐function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD publication-title: Blood – volume: 121 start-page: 71 year: 2009 end-page: 84 article-title: Laboratory diagnosis and molecular classification of von Willebrand disease publication-title: Acta Haematol – volume: 351 start-page: 683 year: 2004 end-page: 94 article-title: Treatment of von Willebrand's Disease publication-title: N Engl J Med – volume: 4 start-page: 2103 year: 2006 end-page: 14 article-title: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor publication-title: J Thromb Haemost – volume: 10 start-page: 199 year: 2004 end-page: 217 article-title: The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization publication-title: Haemophilia – volume: 81 start-page: 1787 year: 1993 end-page: 91 article-title: Pseudo‐von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor publication-title: Blood – volume: 63 start-page: 312 year: 1990 end-page: 5 article-title: Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes publication-title: Thromb Haemost – volume: 124 start-page: S2 issue: Suppl. 1 year: 2009 end-page: 6 article-title: Classification of inherited von Willebrand disease and implications in clinical practice publication-title: Thromb Res – volume: 32 start-page: 307 year: 1983 end-page: 17 article-title: Measurement in medicine: the analysis of method comparison studies publication-title: Statistician – volume: 8 start-page: 2842 year: 2010 end-page: 4 article-title: Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay publication-title: J Thromb Haemost – volume: 52 start-page: 2708 year: 1973 end-page: 16 article-title: Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content publication-title: J Clin Invest – volume: 15 start-page: 505 year: 2004 end-page: 11 article-title: A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000) publication-title: Blood Coagul Fibrinolysis – volume: 84 start-page: 366 year: 2009 end-page: 70 article-title: Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines publication-title: Am J Hematol – ident: e_1_2_6_3_1 doi: 10.1016/S0049-3848(09)70150-1 – ident: e_1_2_6_4_1 doi: 10.1056/NEJMra040403 – ident: e_1_2_6_22_1 doi: 10.1002/ajh.21405 – ident: e_1_2_6_2_1 doi: 10.1054/blre.1999.0116 – volume: 21 start-page: 178 year: 2008 ident: e_1_2_6_9_1 article-title: Lower limit of assay sensitivity: an under‐recognised and significant problem in von Willebrand disease identification and classification publication-title: Clin Lab Sci – ident: e_1_2_6_12_1 doi: 10.1111/j.1365-2516.2010.02419.x – ident: e_1_2_6_8_1 doi: 10.1055/s-0038-1651343 – ident: e_1_2_6_17_1 doi: 10.2307/2987937 – ident: e_1_2_6_20_1 doi: 10.1111/j.1538-7836.2010.04123.x – ident: e_1_2_6_15_1 doi: 10.1055/s-0038-1645215 – ident: e_1_2_6_16_1 doi: 10.1055/s-0037-1614063 – ident: e_1_2_6_21_1 doi: 10.3109/00313029309084791 – ident: e_1_2_6_7_1 doi: 10.1111/j.1365-2516.2004.00894.x – volume: 81 start-page: 1787 year: 1993 ident: e_1_2_6_10_1 article-title: Pseudo‐von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor publication-title: Blood doi: 10.1182/blood.V81.7.1787.1787 – ident: e_1_2_6_14_1 doi: 10.1097/00001721-200408000-00011 – ident: e_1_2_6_5_1 doi: 10.1172/JCI107465 – ident: e_1_2_6_13_1 doi: 10.1046/j.1365-2516.2002.00672.x – ident: e_1_2_6_18_1 doi: 10.1055/s-0038-1642471 – ident: e_1_2_6_6_1 doi: 10.1111/j.1538-7836.2006.02146.x – ident: e_1_2_6_11_1 doi: 10.1182/blood-2010-08-299016 – ident: e_1_2_6_19_1 doi: 10.1159/000214846 |
| SSID | ssj0013206 |
| Score | 2.2786634 |
| Snippet | Summary
The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's... The ristocetin cofactor assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity in the diagnosis of von Willebrand's Disease... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 338 |
| SubjectTerms | Antibodies, Monoclonal Enzyme-Linked Immunosorbent Assay - methods Humans Receptors, GABA-B - metabolism Reproducibility of Results ristocetin cofactor von Willebrand Diseases - diagnosis von Willebrand factor von Willebrand Factor - analysis VWD VWF VWF Ac VWF:RCo |
| Title | A comparative evaluation of a new automated assay for von Willebrand factor activity |
| URI | https://api.istex.fr/ark:/67375/WNG-FKCVR3SB-7/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhae.12064 https://www.ncbi.nlm.nih.gov/pubmed/23205618 https://www.proquest.com/docview/1289479991 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEB-sgvSlH9rq2VaiiPiyx26SS3bp09V6PVoq4kf1obAk2SyCZU_0rrT96zuT_fADhdK3fZgN2Uwm85udyW8AtlwqvcsUxiZOKAxQTBJl1uooEVoaj_5EmlAgu6_GJ_Lz2eBsDt63d2FqfojuhxtZRjivycCNvb5l5OfG9xOOHhXP30Qo4s3_eMhvZRBCX01qQBelPFENqxBV8XRv3vFFC7Ssvx4Cmndxa3A8o-fwvZ1yXW9y0Z9Nbd_9ucfm-J_f9AKeNYCUDesd9BLmfLUEi1-blPsyHA-Zu2EIZzfs4GxSMsMQlTMzm04Q-PqCIRI3vxniYPYTBehfDuWlq4LVbX0Y3aKgZhWv4GS0d7w7jppWDJFDhyWjgStiDCwKVKOLM24xzhFZIRAwpZrHTlL-0JSlUmVSGs2Vo8afsSiNtYV1aSxew3w1qfwqMK-14IV2wnGH6MGZMvFCx94kKvNS-R7stErJXcNTTu0yfuRtvIKrlIdV6sFmJ3pZk3M8JLQdNNtJmKsLqmbTg_x0_1M--rL77VAcfch1DzZa1edoY5Q4MZWfzK5xnDSTmqB0D1bqPdGNhoiUgrAUpx00-_hE8vFwLzys_bvoG3jKQ_8NKnp7C_PTq5l_hyhoatfhCZcH62HT_wXVSwDR |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-NVYK9IMbXyr48hBAvQYnt2om0lzK1K2tXIeigb5bjOEICpWi0aPz33DlptkmbxFseLpZ1l8v9zne-H8Abl0rvMoW5iRMKExSbRFme6ygRWlqP8UTa0CA7VaMLeTbvzTfgeH0Xpp4P0R64kWeE_zU5OB1I3_Dy79a_TziG1AfQkYjLqaGPy083agiBWZMo6KKUJ6qZK0R9PO2rt6JRhxR7dRfUvI1cQ-gZPoHHDWZk_drI27Dhq6fw8Lypij-DWZ-56yHe7HqAN1uUzDIEzsyulgvEpr5gCJbtX4ZQlf1BATpuodJxVbCaeYfRRQfik3gOF8PB7GQUNWwJkcOYIqOeK2LE_gVq2sUZzzEVEVkhENOkmsdOUonPlqVSZVJazZUjbs5YlDbPi9ylsXgBm9Wi8jvAvNaCF9oJxx0GeGfLxAsde5uozEvlu_BurTXjmlHixGjx06xTClSwCQruwutW9Fc9P-MuobdB9a2EvfxBDWe6Z75NT81wfPL1s_jyweguHK1tY9ANqLZhK79Y_cZ10kxqQrtdeFkbrV0NQSPlSSluO1jx_o2YUX8QHl79v-ghPBrNzidm8nE63oUtHugyqEdtDzaXlyu_j6BlmR-Eb_MfGXvjag |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVqq4AOXRLtDWIIS4ZJXYXjtRT9vHslBYodJCD0iW4zhCKspWZRdBf31nnEcfKhLilsPEcjyezDee8XwAr1wqvcsUxiZOKAxQbBJlea6jRGhpPfoTaUOB7ESNj-T748HxAmy1d2Hq_hDdgRtZRvhfk4GfFuUVI_9ufT_h6FHvwJJUiCQIER3wKymEQKxJDHRRyhPVtBWiMp7u1WvOaInW9fdtSPM6cA2eZ3QfvrVzrgtOTvrzWd535zfaOf7nRz2Aew0iZcN6C63Agq8ewvLHJuf-CA6HzF22CGeX7cHZtGSWISxndj6bIvL1BUMobv8wBMLsFwrQYQ4lpquC1bw-jK5REFvFYzga7R3ujKOGiyFy6LFkNHBFjJFFgXp0ccZzDHREVghETKnmsZOUQLRlqVSZlFZz5Yj5MxalzfMid2ksnsBiNa38GjCvteCFdsJxh_DB2TLxQsfeJirzUvkevGmVYlzTqJz4Mn6YNmDBVTJhlXrwshM9rbtz3Cb0Omi2k7BnJ1TOpgfm6-StGe3vfDkQn7eN7sGLVvUGjYwyJ7by0_lPHCfNpCYs3YPVek90oyEkpSgsxWkHzf59ImY83AsPT_9ddBOWP-2OzId3k_1ncJcHLg4qgHsOi7OzuV9HRDTLN8LOvwDLugLI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comparative+evaluation+of+a+new+automated+assay+for+von+Willebrand+factor+activity&rft.jtitle=Haemophilia+%3A+the+official+journal+of+the+World+Federation+of+Hemophilia&rft.au=Lawrie%2C+A.+S.&rft.au=Stufano%2C+F.&rft.au=Canciani%2C+M.+T.&rft.au=Mackie%2C+I.+J.&rft.date=2013-03-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1351-8216&rft.eissn=1365-2516&rft.volume=19&rft.issue=2&rft.spage=338&rft.epage=342&rft_id=info:doi/10.1111%2Fhae.12064&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_FKCVR3SB_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-8216&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-8216&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-8216&client=summon |